Mechanics of poly-arginine adsorption onto cell membrane by GM1 and their cluster forming: coarse-grained molecular dynamics study

Journal of Molecular Structure, Год журнала: 2024, Номер 1322, С. 140690 - 140690

Опубликована: Ноя. 9, 2024

Язык: Английский

---

Reduction in Hippocampal Aβ Content During Gly-Pro-Glu Co-Administration Is Associated with Changes in Inflammation and IGF-I Signaling

Опубликована: Апрель 18, 2024

Alzheimer´s disease (AD) is characterized by the brain deposition of senile plaques composed amyloid-β peptides (Aβ) that increase inflammation. An endogenous peptide derived from insulin-like growth factor (IGF)-I, glycine-proline-glutamate (GPE) has IGF-I-sensitizing and neuroprotective actions. Here, we examined effects GPE on Aβ levels hippocampal inflammation generated intracerebroventricular infusion Aβ25-35 during 2 weeks (300 pmol/day) in ovariectomized rats signaling-related pathways Aβ-degrading enzymes associated with these GPE-related effects. prevented Aβ-induced phosphorylation p38 mitogen-activated protein kinase reduction activation signal transducer activator transcription 3, insulin receptor substrate-1 Akt, as well interleukin (IL)-2 IL-13 hippocampus. The functionality somatostatin, measured percentage inhibition adenylate cyclase activity insulin-degrading enzyme were also preserved co-treatment. These findings indicate co-administration may protect insult changing cytokine content somatostatin through regulation leptin- IGF-I-signaling could influence modulation and/or proteases.

Язык: Английский

---

Reduction in Hippocampal Amyloid-β Peptide (Aβ) Content during Glycine-Proline-Glutamate (Gly-Pro-Glu) Co-Administration Is Associated with Changes in Inflammation and Insulin-like Growth Factor (IGF)-I Signaling

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(11), С. 5716 - 5716

Опубликована: Май 24, 2024

Alzheimer’s disease (AD) is characterized by the deposition in brain of senile plaques composed amyloid-β peptides (Aβs) that increase inflammation. An endogenous peptide derived from insulin-like growth factor (IGF)-I, glycine-proline-glutamate (GPE), has IGF-I-sensitizing and neuroprotective actions. Here, we examined effects GPE on Aβ levels hippocampal inflammation generated intracerebroventricular infusion Aβ25-35 for 2 weeks (300 pmol/day) ovariectomized rats signaling-related pathways Aβ-degrading enzymes associated with these GPE-related effects. prevented Aβ-induced phosphorylation p38 mitogen-activated protein kinase reduction activation signal transducer activator transcription 3, insulin receptor substrate-1, Akt, as well interleukin (IL)-2 IL-13 hippocampus. The functionality somatostatin, measured percentage inhibition adenylate cyclase activity insulin-degrading enzyme, was also preserved co-treatment. These findings indicate co-administration may protect insult changing cytokine content somatostatin through regulation leptin- IGF-I-signaling could influence modulation and/or proteases.

Язык: Английский

---

Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management

International Urology and Nephrology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 4, 2024

Язык: Английский

---

Synthesis and Characterization of Transferrin and Cell-Penetrating Peptide-Functionalized Liposomal Nanoparticles to Deliver Plasmid ApoE2 In Vitro and In Vivo in Mice

Molecular Pharmaceutics, Год журнала: 2024, Номер 22(1), С. 229 - 241

Опубликована: Дек. 12, 2024

Alzheimer's disease (AD) is a prevalent neurodegenerative condition characterized by the aggregation of amyloid-β plaques and neurofibrillary tangles in brain, leading to synaptic dysfunction neuronal degeneration. Recently, new treatment approaches involving drugs such as donanemab lecanemab have been introduced for AD. However, these drug regimens associated with adverse effects, exploration gene therapy potential option. The apolipoprotein E (ApoE) isoforms (ApoE2, ApoE3, ApoE4) play pivotal roles AD pathology, ApoE2 known its protective effects against AD, making it promising candidate interventions. delivering therapeutics across blood-brain barrier (BBB) remains crucial challenge treating neurological disorders. Liposomes, lipid-based vesicles, are effective nanocarriers due their ability shield from degradation, though they often lack specificity brain delivery. To address this issue, liposomes were functionalized cell-penetrating peptides penetratin (Pen), cingulin (Cgn), targeting ligand transferrin (T

Язык: Английский

---

Insights of nose to brain delivery in treating Parkinson’s disease: A systematic review

Journal of Applied Pharmaceutical Research, Год журнала: 2024, Номер 12(6), С. 57 - 72

Опубликована: Дек. 31, 2024

Background: In Parkinson's disease (PD), a complicated neurodegenerative ailment, neurons in the substantia nigra that produce dopamine are lost, resulting an insufficiency of neurotransmitter is essential for regulation voluntary and smooth muscular movements. This review focuses on obstacle triggering effectiveness traditional PD treatments, which blood-brain barrier (BBB), prevents some therapeutic medicines from reaching brain. It encompasses potential strategy nose-to-brain administration by innovative approaches, including nanoparticles, liposomes, dendrimers, cell-based carriers, directly delivering drugs nose to Methods: The methodology involved examining characteristics, advantages, applications, challenges various nanoparticles like SLNs, Nanoliposomes, Quantum dots, etc., through meticulous analysis articles PubMed (5), ScienceDirect Bentham Science (4) Scopus databases (5). Conclusion: concludes emphasizing applications circumventing problems encountered with methods drug treating PD. detailed study brings light need be faced utilizing delivery. Attention directed towards enlightenment advanced carriers target specific brain regions via olfactory trigeminal routes. reaches brain, bypassing BBB.

Язык: Английский

---